Long-Term Efficacy of Vismodegib After its Withdrawal and Patients ’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)
ConclusionThe results of this exploratory analysis of vismodegib withdrawal are consistent with a substantial link between treatment response and patients ’ HRQoL. Furthermore, 11 out of 35 (31%) patients that reported a complete remission of the disease after 6 months of vismodegib treatment reported BCC recurrence. These data highlight the importance of continuous follow-up and perhaps different regimens of treatment, such as an alternate dose re gimen to maintain disease control and reduce the adverse events as previously described in the literature.
Authors: deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Ståhle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C, Srivastava B, Krueger G Abstract To the Editor: Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated among those who previously received systemic treatment or phototherapy.2 Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase suscept...
Non-melanoma skin cancer (NMSC) is the most common cancer worldwide. Australia has the highest incidence of skin cancer in the world, exceeding 2000 per 100 000 person-years and it is increasing . In the USA, more than 3 million individuals are diagnosed with NMSC each year [2,3]. In the UK, during 2014–2016, about 147 000 new NMSC cases were diagnosed every year, more than 400 every day . Data show that between 1976 and 1984, the overall inc idence of basal cell carcinoma (BCC) increased by 145% and of cutaneous squamous cell carcinoma (cSCC) by 263%.
Transplant recipients have a significantly higher risk of developing non-melanoma skin cancers compared with the general population and squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common post-transplant malignancies. Although in the general population BCC outnumbers SCC 4:1, in transplant patients this ratio is reversed and SCC is more common, with a 65- to 250-fold increased incidence. As patients in immunosuppressed states are living longer after transplants, the incidence of skin cancer in this population continues to increase.
AbstractPurpose of ReviewThe aim of this work is to review the role of advanced non-invasive imaging, such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), in malignant melanomas and non-melanoma skin cancers (NMSCs) using data coming from the most recent literature, with a particular highlight on the results of the European experience.Recent FindingsExamination with RCM and OCT increases the accuracy of diagnosis. The most recent diagnostic clues for melanoma and NMSCs are revised. In addition, the application of these techniques in presurgical margin definition and in monitoring the effica...
ConclusionsThis study brings out consequential information on factors linked with invaded or insufficient excision margins. Larger cohorts should evaluate the aesthetic outcomes in such a population.
ConclusionThis is the first study to demonstrate a significant change in patient health-related quality of life from baseline to 6 months after hedgehog pathway inhibitor therapy initiation using the DLQI test. Interestingly, patients with BCC in visible areas such as the face or neck presented an overall DLQI score that was higher than that of patients with BCC located on the trunk and legs at the baseline visit, but the DLQI scores of these two groups were almost the same after 6 months of vismodegib therapy.
CONCLUSIONS: Our large study suggests that prevention of melanoma in NMSC patients is mandatory, especially for patients which develop a NMSC under 40 years of age. PMID: 31042854 [PubMed - as supplied by publisher]
Conclusions: Our results underestimate the direct costs of nmsc because inpatient services and non-physician costs were not included in the calculations. The present research represents a first step in understanding the cost burden of nmsc in Saskatchewan. PMID: 31043813 [PubMed - in process]
The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers.
Surgery is a standard treatment for patients suffering from non-melanoma skin cancer. However, postoperative relapse or positive margins after surgery are linked with worse outcome. We aimed to analyze surface high-dose-rate brachytherapy as an adjuvant/salvage option.